Results 171 to 180 of about 106,528 (297)

Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available.
Emily Goddard, Aaron Keal, James Hetherington, Sophie Barlow, David Wu, Melany Worbes‐Cerezo, Alexander Litvintchouk   +6 more
wiley   +1 more source

<i>Cutibacterium acnes</i>-macrophage fusion membrane coating Cu/Zn-MOF for psoriasis treatment via pathological innate lymphoid cells inhibition. [PDF]

Mater Today Bio
Zhang J, Gao Y, Le D, Peng Y, Wang H, Lu X, Liu L, Li Y, Wang J, Fan Z, Hu Z, Cheng B, Gan Y, Du L.   +13 more
europepmc   +1 more source

Customized flexible hollow microneedles for psoriasis treatment with reduced-dose drug. [PDF]

Bioeng Transl Med, 2023
Ren Y, Li J, Chen Y, Wang J, Chen Y, Wang Z, Zhang Z, Chen Y, Shi X, Cao L, Zhang J, Dong H, Yan C, Li Z.   +13 more
europepmc   +1 more source

Impact of tobacco smoking and alcohol consumption on the treatment efficacy among psoriasis patients: A study protocol [PDF]

Fanlingzi Shen, Yaping Ding, Ruiping Wang   +2 more
openalex   +1 more source

Concurrent Psoriasis and Dermatomyositis: Retrospective Analysis and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis (PsO) and dermatomyositis (DM) are both autoimmune‐mediated, inflammatory conditions. The concurrence of PsO and DM is rare, and literature on their relationship remains limited. Additionally, cutaneous DM can be challenging to clinically diagnosis, often presenting with psoriasiform clinical features.
Emily R. Gordon, Karishma S. Shah, Sidharth Chand, Bonnie Lee, Janellen Smith, Michelle S. Min   +5 more
wiley   +1 more source

Therapeutic Potential of Curcumin and Novel Formulations in Psoriasis Treatment: Evidence and Future Prospects. [PDF]

Drug Des Devel Ther
Kantasa T, Yeerong K, Klinjan P, Na Takuathung M, Settakorn K, Chuamanochan M, Tovanabutra N, Ampasavate C, Koonrungsesomboon N.   +8 more
europepmc   +1 more source

Development and validation of a psoriasis treatment acceptability measure through group concept mapping. [PDF]

Health Qual Life Outcomes, 2023
Hudgens S, Howerter A, Keith S, Evans C, Pelletier C.   +4 more
europepmc   +1 more source

Narrow band UVB monotherapy versus topical calcipotriol ointment combined with narrow band UVB phototherapy for treatment of psoriasis vulgaris

, 2015
Nadia Abdalhafid Elsherif, Ibtisam Elmangush, Salwa Abdalsalam El-Dibany   +2 more
openalex   +1 more source

Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

, 2021
Roberto Ravasio, Antonio Costanzo, Silvia Antonelli, Alessia Maiorino, Serena Losi   +4 more
openalex   +2 more sources

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos, Line Kibsgaard, Trine Bertelsen   +2 more
wiley   +1 more source